Guardant Health (NASDAQ:GH) Director Medina Manuel Hidalgo Sells 1,700 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,700 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $164.24, for a total value of $279,208.00. Following the completion of the transaction, the director owned 4,556 shares of the company’s stock, valued at $748,277.44. The trade was a 27.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Thursday, May 28th, Medina Manuel Hidalgo sold 1,000 shares of Guardant Health stock. The stock was sold at an average price of $130.06, for a total value of $130,060.00.
• On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The shares were sold at an average price of $107.09, for a total value of $133,862.50.

Guardant Health Stock Down 3.4%

Shares of Guardant Health stock opened at $157.58 on Friday. Guardant Health, Inc. has a 52 week low of $48.25 and a 52 week high of $176.58. The business’s fifty day simple moving average is $146.24 and its 200-day simple moving average is $114.82. The firm has a market cap of $21.15 billion, a PE ratio of -45.15 and a beta of 1.60.

Institutional Trading of Guardant Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Persistent Asset Partners Ltd acquired a new stake in shares of Guardant Health during the second quarter worth about $641,000. OneDigital Investment Advisors LLC acquired a new position in shares of Guardant Health in the second quarter valued at approximately $345,000. Trivium Point Advisory LLC purchased a new stake in Guardant Health during the 2nd quarter worth approximately $819,000. Global Retirement Partners LLC acquired a new stake in Guardant Health during the 2nd quarter worth approximately $59,000. Finally, State of Wyoming purchased a new position in Guardant Health in the 2nd quarter valued at approximately $393,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GH has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Friday, July 17th. The Goldman Sachs Group reissued a “buy” rating and issued a $210.00 price target on shares of Guardant Health in a research note on Friday, July 31st. BTIG Research upped their price objective on shares of Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Evercore reiterated an “outperform” rating and issued a $200.00 target price on shares of Guardant Health in a report on Monday, July 6th. Finally, TD Cowen boosted their target price on Guardant Health from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.